What 4 Analyst Ratings Have To Say About Regenxbio
Portfolio Pulse from Benzinga Insights
In the past three months, four analysts have rated Regenxbio (NASDAQ:RGNX) with varying perspectives. The average 12-month price target is $36.5, down from $44.00. Analysts' actions include maintaining, raising, and lowering ratings, reflecting their views on Regenxbio's market performance. The company shows strong revenue growth and efficient financial management, despite negative net margins and returns.
October 10, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Regenxbio has received mixed analyst ratings with a current average price target of $36.5, down from $44.00. Analysts have varied in their actions, with some maintaining, raising, or lowering their ratings. The company's financials show strong revenue growth but negative net margins and returns.
The mixed analyst ratings and lowered price target suggest uncertainty in the short-term stock performance. While the company shows strong revenue growth, negative net margins and returns may concern investors. The neutral score reflects the balance of positive and negative factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100